Keller Alexandre C, Mucida Daniel, Gomes Eliane, Faquim-Mauro Eliana, Faria Ana Maria Caetano, Rodriguez Dunia, Russo Momtchilo
Department of Immunology, Biomedical Science Institute, University of São Paulo, Brazil.
J Allergy Clin Immunol. 2006 Feb;117(2):283-90. doi: 10.1016/j.jaci.2005.10.019.
Mucosal tolerance can be induced by oral or nasal administration of soluble proteins and results in the suppression of cellular and/or humoral immune responses to the specific antigen.
To compare the effect of oral or nasal ovalbumin administration before, during or after immunization on the development of cellular and humoral immune responses by using a murine asthma model.
To induce lung allergic inflammation, animals were immunized twice with ovalbumin/aluminum hydroxide gel and challenged twice with ovalbumin. To induce tolerance, BALB/c mice received ovalbumin by the oral or nasal routes for 3 consecutive days. The ovalbumin administration was initiated before (day -7), during (day 0), or after immunization (day 7).
Airway eosinophilia, airway hyperreactivity, mucus hypersecretion, and cytokine production were suppressed when oral or nasal ovalbumin administration was initiated before immunization. Oral but not nasal ovalbumin exposure suppressed ovalbumin-specific nonanaphylactic IgG(1) antibodies, whereas both routes suppressed the production of anaphylactic IgG(1) and IgE antibodies. Mucosal ovalbumin administration at day 0 inhibited all T(H)2-mediated allergic parameters but not nonanaphylactic IgG(1) antibodies. Finally, ovalbumin exposure 7 days after immunization was still effective in suppressing lung allergy but not ovalbumin-specific anaphylactic IgG(1) and IgE antibodies.
We show that the effectiveness of mucosal tolerance depends on route and time and presents a hierarchical pattern of suppression in the following order: lung allergic responses > anaphylactic antibodies > ovalbumin-specific IgG(1).
口服或鼻内给予可溶性蛋白质可诱导黏膜耐受,并导致对特定抗原的细胞和/或体液免疫反应受到抑制。
利用小鼠哮喘模型比较免疫前、免疫期间或免疫后口服或鼻内给予卵清蛋白对细胞和体液免疫反应发展的影响。
为诱导肺部过敏性炎症,动物用卵清蛋白/氢氧化铝凝胶免疫两次,并用卵清蛋白激发两次。为诱导耐受,BALB/c小鼠连续3天通过口服或鼻内途径接受卵清蛋白。卵清蛋白给药在免疫前(第-7天)、免疫期间(第0天)或免疫后(第7天)开始。
当在免疫前开始口服或鼻内给予卵清蛋白时,气道嗜酸性粒细胞增多、气道高反应性、黏液分泌过多和细胞因子产生均受到抑制。口服而非鼻内给予卵清蛋白可抑制卵清蛋白特异性非过敏性IgG(1)抗体,而两种途径均抑制过敏性IgG(1)和IgE抗体的产生。在第0天给予黏膜卵清蛋白可抑制所有T(H)2介导的过敏参数,但不抑制非过敏性IgG(1)抗体。最后,免疫后7天给予卵清蛋白仍可有效抑制肺部过敏,但不抑制卵清蛋白特异性过敏性IgG(1)和IgE抗体。
我们表明黏膜耐受的有效性取决于途径和时间,并呈现出以下抑制等级模式:肺部过敏反应>过敏性抗体>卵清蛋白特异性IgG(1)。